{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+Control&page=41",
    "query": {
      "intervention": "Vehicle Control",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 1097,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+Control&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+Control&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T03:06:25.594Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04598269",
      "title": "Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "ATI-1777",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-09-30",
      "completion_date": "2021-04-22",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Encino, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04598269"
    },
    {
      "nct_id": "NCT02813265",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "KPI-121 0.25% Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of KPI-121 0.25% Ophthalmic Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 918,
      "start_date": "2016-06",
      "completion_date": "2017-10",
      "has_results": true,
      "last_update_posted_date": "2021-02-03",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 60,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02813265"
    },
    {
      "nct_id": "NCT03662854",
      "title": "Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alopecia"
      ],
      "interventions": [
        {
          "name": "Hair Stimulating Complex (HSC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate Buffered Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Histogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 70 Years · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2018-07-02",
      "completion_date": "2021-01-21",
      "has_results": false,
      "last_update_posted_date": "2019-02-21",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03662854"
    },
    {
      "nct_id": "NCT05550337",
      "title": "Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Trifarotene 0.005 % Topical Cream",
          "type": "DRUG"
        },
        {
          "name": "AKLIEF®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 807,
      "start_date": "2022-09-19",
      "completion_date": "2023-05-09",
      "has_results": true,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 14,
      "location_summary": "West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more",
      "locations": [
        {
          "city": "West Covina",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05550337"
    },
    {
      "nct_id": "NCT06016972",
      "title": "Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma (POAG)",
        "Primary Open Angle Glaucoma of Both Eyes",
        "Primary Open-Angle Glaucoma, Unspecified Eye",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "Experimental: QLS-111 ophthalmic solution, (0.015%)",
          "type": "DRUG"
        },
        {
          "name": "Experimental: QLS-111 ophthalmic solution, (0.03%)",
          "type": "DRUG"
        },
        {
          "name": "Experimental: QLS-111 ophthalmic solution, (0.075%)",
          "type": "DRUG"
        },
        {
          "name": "QLS-111 ophthalmic vehicle solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Qlaris Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2024-03-05",
      "completion_date": "2024-08-20",
      "has_results": false,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 1,
      "location_summary": "Roswell, Georgia",
      "locations": [
        {
          "city": "Roswell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06016972"
    },
    {
      "nct_id": "NCT04057573",
      "title": "Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-segmental Vitiligo"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 344,
      "start_date": "2019-10-03",
      "completion_date": "2021-10-01",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 34,
      "location_summary": "Gilbert, Arizona • Fremont, California • Irvine, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04057573"
    },
    {
      "nct_id": "NCT04055090",
      "title": "Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Painful Diabetic Neuropathy",
        "Diabetic Neuropathy, Painful"
      ],
      "interventions": [
        {
          "name": "Long-Term Follow-Up of Patients who Received Engensis (VM202)",
          "type": "GENETIC"
        },
        {
          "name": "Long-Term Follow-Up of Patients who Received Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Helixmith Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 101,
      "start_date": "2019-02-04",
      "completion_date": "2019-07-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-09",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04055090"
    },
    {
      "nct_id": "NCT03571620",
      "title": "Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Q301 Cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qurient Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "12 Years to 70 Years"
      },
      "enrollment_count": 258,
      "start_date": "2018-06-21",
      "completion_date": "2020-04-21",
      "has_results": false,
      "last_update_posted_date": "2020-04-24",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03571620"
    },
    {
      "nct_id": "NCT03229759",
      "title": "Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Preoperative Skin Preparation"
      ],
      "interventions": [
        {
          "name": "Octenidine Dihydrocloride in aqueous solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Control",
          "type": "OTHER"
        },
        {
          "name": "Saline Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Becton, Dickinson and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2017-06-21",
      "completion_date": "2017-08-04",
      "has_results": true,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 1,
      "location_summary": "Bozeman, Montana",
      "locations": [
        {
          "city": "Bozeman",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03229759"
    },
    {
      "nct_id": "NCT03175354",
      "title": "A Study in Subjects With Moderate Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Eczema, Atopic"
      ],
      "interventions": [
        {
          "name": "ALX-101 Gel 1.5% and ALX-101 Gel Vehicle",
          "type": "DRUG"
        },
        {
          "name": "ALX-101 Gel 5% and ALX-101 Gel Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ralexar Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 209,
      "start_date": "2017-04-26",
      "completion_date": "2018-06-29",
      "has_results": false,
      "last_update_posted_date": "2018-10-25",
      "last_synced_at": "2026-10-22T03:06:25.594Z",
      "location_count": 35,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03175354"
    }
  ]
}